🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to health experts.

An International Health Concern

The sexually transmitted infection are escalating around the world, with figures suggesting in excess of 82 million infections per year. Notably increased rates are seen in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, the spread of superbugs and the very limited treatment choices presently on offer.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Secure Approval

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts hope that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, was also approved in the same week. This treatment, which is also used to treat UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This approval signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Testing Results and Worldwide Availability

According to data detailed in a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This puts it on an equal footing with the current standard treatment, which involves a dual-drug approach. The study involved over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Clinicians directly involved have shared hope. Access to a one-pill regimen like this is seen as a "revolutionary step" for public health efforts. This is deemed vital to reduce the burden of the disease for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.